Hepatitis B Treatment Market Research Report, By Type (Acute and Chronic), Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, and Surgery (Liver Transplant)), and Distribution Channel (Hospital & Retail Pharmacies)- Forecast till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Pricing Analysis

Chapter 6. Global Hepatitis B Treatment Market, by Type

6.1 Introduction

6.2 Acute

6.3 Chronic

Chapter 7. Global Hepatitis B Treatment Market, by Treatment

7.1 Introduction

7.2 Immune Modulator Drugs

7.2.1 Pegylated Interferon

7.2.2 Interferon Alpha

7.3 Antiviral Drugs

7.3.1 Tenofovir disoproxil

7.3.2 Entecavir

7.3.3 Telbivudine

7.3.4 Lamivudine

7.3.5 Others

7.4 Vaccine

7.5 Surgery (Liver Transplant)

Chapter 8. Global Hepatitis B Treatment Market, by Distribution Channel

8.1 Introduction

8.2 Hospital & Retail Pharmacies

8.3 Online Pharmacies

Chapter 9. Global Hepatitis B Treatment Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Accord Healthcare Inc.

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Apotex Corp.

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Arbutus Biopharma

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Arrowhead Pharma

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Aurobindo Pharma Limited

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Bristol-Myers Squibb Company

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Gilead Sciences, Inc.

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 GlaxoSmithKline

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Lupin Pharmaceuticals, Inc.

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Merck & Co., Inc.

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Par Pharmaceutical, Inc.

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Teva Pharmaceuticals

11.12.1 Overview

11.12.2 Type Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Zydus Pharmaceuticals

11.13.1 Overview

11.13.2 Type Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Hepatitis B Treatment Market Industry Synopsis, 2020–2027

Table 2 Global Hepatitis B Treatment Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Hepatitis B Treatment Market, by Region, 2020–2027, (USD Million)

Table 4 Global Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 5 Global Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 6 Global Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 7 North America: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 8 North America: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 10 US: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 11 US: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 12 US: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 13 Canada: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 14 Canada: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 16 Latin America: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 17 Latin America: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 18 Latin America: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 19 Europe: Hepatitis B Treatment Market, Type, 2020–2027, (USD Million)

Table 20 Europe: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 22 Western Europe: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 23 Western Europe: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 25 Eastern Europe: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 26 Eastern Europe: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 28 Asia-Pacific: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 29 Asia-Pacific: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia-Pacific: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

Table 31 Middle East & Africa: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

Table 32 Middle East & Africa: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 33 Middle East & Africa: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Hepatitis B Treatment Market

Figure 3 Market Dynamics for the Global Hepatitis B Treatment Market

Figure 4 Global Hepatitis B Treatment Market Share, by Type 2020

Figure 5 Global Hepatitis B Treatment Market Share, by Treatment, 2020

Figure 6 Global Hepatitis B Treatment Market Share, by Distribution Channel, 2020

Figure 7 Global Hepatitis B Treatment Market Share, by Region, 2020

Figure 8 North America Hepatitis B Treatment Market Share, by Country, 2020

Figure 9 Europe Hepatitis B Treatment Market, by Country, 2020

Figure 10 Asia-Pacific Hepatitis B Treatment Market Share, by Country, 2020

Figure 11 Middle East & Africa Hepatitis B Treatment Market Share, by Country, 2020

Figure 12 Global Hepatitis B Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 Accord Healthcare Inc.: Key Financials

Figure 14 Accord Healthcare Inc.: Segmental Revenue

Figure 15 Accord Healthcare Inc.: Geographical Revenue

Figure 16 Apotex Corp.: Key Financials

Figure 17 Apotex Corp.: Segmental Revenue

Figure 18 Apotex Corp.: Geographical Revenue

Figure 19 Arbutus Biopharma: Key Financials

Figure 20 Arbutus Biopharma: Segmental Revenue

Figure 21 Arbutus Biopharma: Geographical Revenue

Figure 22 Arrowhead Pharma: Key Financials

Figure 23 Arrowhead Pharma: Segmental Revenue

Figure 24 Arrowhead Pharma: Geographical Revenue

Figure 25 Aurobindo Pharma Limited: Key Financials

Figure 26 Aurobindo Pharma Limited: Segmental Revenue

Figure 27 Aurobindo Pharma Limited: Geographical Revenue

Figure 28 Bristol-Myers Squibb Company: Key Financials

Figure 29 Bristol-Myers Squibb Company: Segmental Revenue

Figure 30 Bristol-Myers Squibb Company: Geographical Revenue

Figure 31 Gilead Sciences, Inc.: Key Financials

Figure 32 Gilead Sciences, Inc.: Segmental Revenue

Figure 33 Gilead Sciences, Inc.: Geographical Revenue

Figure 34 Royal DSM: Key Financials

Figure 35 Royal DSM: Segmental Revenue

Figure 36 Royal DSM: Geographical Revenue

Figure 37 Merck & Co., Inc.: Key Financials

Figure 38 Merck & Co., Inc.: Segmental Revenue

Figure 39 Merck & Co., Inc.: Geographical Revenue

Figure 40 Straumann Holding AG: Key Financials

Figure 41 Straumann Holding AG: Segmental Revenue

Figure 42 Straumann Holding AG: Geographical Revenue

Figure 43 Zimmer Biomet Holdings, Inc.: Key Financials

Figure 44 Zimmer Biomet Holdings, Inc.: Segmental Revenue

Figure 45 Zimmer Biomet Holdings, Inc.: Geographical Revenue

Figure 46 Teva Pharmaceuticals: Key Financials

Figure 47 Teva Pharmaceuticals: Segmental Revenue

Figure 48 Teva Pharmaceuticals: Geographical Revenue

Figure 49 Zydus Pharmaceuticals: Key Financials

Figure 50 Zydus Pharmaceuticals: Segmental Revenue

Figure 51 Zydus Pharmaceuticals: Geographical Revenue